Using thymine-18 for enhancing dose delivery and localizing the Bragg peak in proton-beam therapy
arXiv:2102.09081
Abstract
Therapeutic protons acting on O18-substituted thymidine increase cytotoxicity in radio-resistant human cancer cells. We consider here the physics behind the irradiation during proton beam therapy and diagnosis using O18-enriched thymine in DNA, with attention to the effect of the presence of thymine-18 on cancer cell death.